Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells

Molecular Immunology

Volumn 66, Issue 2, 2015, Pages 310-318

  Xiao, Jing ^a   Fu, Chensheng ^a   Zhang, Xiaoli ^a   Zhu, Dingyu ^a   Chen, Weijun ^a   Lu, Yijun ^a   Ye, Zhibin ^a  

^a HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

Author keywords

Human renal mesangial cells; Immune activation; Monosodium urate crystal; Soluble monosodium urate; Toll like receptor 4

Indexed keywords

CD40 ANTIGEN; CRYOPYRIN; HLA DR ANTIGEN; INTERLEUKIN 1BETA; RESATORVID; TOLL LIKE RECEPTOR 4; URATE; CARRIER PROTEIN; ETHYL 6-(N-(2-CHLORO-4-FLUOROPHENYL)SULFAMOYL)CYCLOHEX-1-ENE-1-CARBOXYLATE; NLRP3 PROTEIN, HUMAN; SULFONAMIDE; TLR4 PROTEIN, HUMAN; URIC ACID;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CRYSTALLIZATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SOLUBILITY;

ANTIGENS, CD40; CARRIER PROTEINS; CRYSTALLIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-1BETA; MESANGIAL CELLS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SOLUBILITY; SULFONAMIDES; TOLL-LIKE RECEPTOR 4; URIC ACID;

EID: 84928118786     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.03.250     Document Type: Article

References (45)

1. Abboud H.E. Mesangial cell biology. Exp. Cell. Res. 2012, 318:979-985.
2. Albertoni G., Maquigussa E., Pessoa E., Barreto J.A., Borges F., Schor N. Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood) 2011, 235:825-832.
3. Bose B., Badve S.V., Hiremath S.S., Boudville N., Brown F.G., Cass A., de Zoysa J.R., Fassett R.G., Faull R., Harris D.C., Hawley C.M., Kanellis J., Palmer S.C., Perkovic V., Pascoe E.M., Rangan G.K., Walker R.J., Walters G., Johnson D.W. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial. Transplant. 2014, 29:406-413.
4. Chavez-Sanchez L., Garza-Reyes M.G., Espinosa-Luna J.E., Chavez-Rueda K., Legorreta-Haquet M.V., Blanco-Favela F. The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans. Hum. Immunol. 2014, 75:322-329.
5. Convento M.S., Pessoa E., Dalboni M.A., Borges F.T., Schor N. Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage. Urol. Res. 2011, 39:21-27.
6. Davis B.K., Wen H., Ting J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011, 29:707-735.
7. Dikshtein E.A., Vasilenko I.V., Siniachenko O.V., Diadyk A.I., Shevchenko N.I. Morphological changes in the kidney glomeruli in gout. Arkh. Patol. 1986, 48:54-58.
8. Eisenbacher J.L., Schrezenmeier H., Jahrsdorfer B., Kaltenmeier C., Rojewski M.T., Yildiz T., Beyer T., Erle A., Wiegmann D.S., Grassl S., Hang R., Korper S., Wiesneth M., Lotze M.T., Lotfi R. S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. J. Immunol. 2014, 192:6102-6110.
9. Fang H., Ang B., Xu X., Huang X., Wu Y., Sun Y., Wang W., Li N., Cao X., Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell. Mol. Immunol. 2014, 11:150-156.
10. Ficociello L.H., Rosolowsky E.T., Niewczas M.A., Maselli N.J., Weinberg J.M., Aschengrau A., Eckfeldt J.H., Stanton R.C., Galecki A.T., Doria A., Warram J.H., Krolewski A.S. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010, 33:1337-1343.
11. Frei R., Steinle J., Birchler T., Loeliger S., Roduit C., Steinhoff D., Seibl R., Buchner K., Seger R., Reith W., Lauener R.P. MHC class II molecules enhance Toll-like receptor mediated innate immune responses. PLoS ONE 2010, 5:e8808.
12. Gluhovschi C., Gluhovschi G., Potencz E., Lazar E., Petrica L., Bozdog G., Gadalean F., Bob F., Cioca D., Velciov S. What is the significance of HLA-DR antigen expression in the extraglomerular mesangium in glomerulonephritis?. Hum. Immunol. 2012, 73:1098-1101.
13. Goicoechea M., de Vinuesa S.G., Verdalles U., Ruiz-Caro C., Ampuero J., Rincon A., Arroyo D., Luno J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 2010, 5:1388-1393.
14. Grainger R., McLaughlin R.J., Harrison A.A., Harper J.L. Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatology (Oxf.) 2013, 52:1018-1021.
15. Han H.J., Lim M.J., Lee Y.J., Lee J.H., Yang I.S., Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am. J. Physiol. Ren. Physiol. 2007, 292:F373-F381.
16. Holzinger D., Nippe N., Vogl T., Marketon K., Mysore V., Weinhage T., Dalbeth N., Pool B., Merriman T., Baeten D., Ives A., Busso N., Foell D., Bas S., Gabay C., Roth J. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol. 2014, 66:1327-1339.
17. Iseki K., Ikemiya Y., Inoue T., Iseki C., Kinjo K., Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am. J. Kidney Dis. 2004, 44:642-650.
18. Ishani A., Grandits G.A., Grimm R.H., Svendsen K.H., Collins A.J., Prineas R.J., Neaton J.D. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J. Am. Soc. Nephrol. 2006, 17:1444-1452.
19. Kamei K., Konta T., Hirayama A., Suzuki K., Ichikawa K., Fujimoto S., Iseki K., Moriyama T., Yamagata K., Tsuruya K., Kimura K., Narita I., Kondo M., Asahi K., Watanabe T. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol. Dial. Transplant. 2014, 29:2286-2292.
20. Kanellis J., Watanabe S., Li J.H., Kang D.H., Li P., Nakagawa T., Wamsley A., Sheikh-Hamad D., Lan H.Y., Feng L., Johnson R.J. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287-1293.
21. Kobayashi T., Kouzaki H., Kita H. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J. Immunol. 2010, 184:6350-6358.
22. Li S., Zhao F., Cheng S., Wang X., Hao Y. Uric acid-induced endoplasmic reticulum stress triggers phenotypic change in rat glomerular mesangial cells. Nephrology (Carlton) 2013, 18:682-689.
23. Liu-Bryan R., Scott P., Sydlaske A., Rose D.M., Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheumatol. 2005, 52:2936-2946.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
25. Lovett D.H., Szamel M., Ryan J.L., Sterzel R.B., Gemsa D., Resch K. Interleukin 1 and the glomerular mesangium, I. Purification and characterization of a mesangial cell-derived autogrowth factor. J. Immunol. 1986, 136:3700-3705.
26. Mandal A., Mount D.B. The molecular physiology of uric acid homeostasis. Annu. Rev. Physiol. 2015, 77:323-345.
27. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
28. Mazzali M., Hughes J., Kim Y.G., Jefferson J.A., Kang D.H., Gordon K.L., Lan H.Y., Kivlighn S., Johnson R.J. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
29. McGettrick A.F., O'Neill L.A. How metabolism generates signals during innate immunity and inflammation. J. Biol. Chem. 2013, 288:22893-22898.
30. Mehindate K., al-Daccak R., Damdoumi F., Mourad W. Synergistic effect between CD40 and class II signals overcome the requirement for class II dimerization in superantigen-induced cytokine gene expression. Eur. J. Immunol. 1996, 26:2075-2080.
31. Moe O.W. Posing the question again: does chronic uric acid nephropathy exist?. J. Am. Soc. Nephrol. 2010, 21:395-397.
32. Mok Y., Lee S.J., Kim M.S., Cui W., Moon Y.M., Jee S.H. Serum uric acid and chronic kidney disease: the severance cohort study. Nephrol. Dial. Transplant. 2012, 27:1831-1835.
33. Obermayr R.P., Temml C., Gutjahr G., Knechtelsdorfer M., Oberbauer R., Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 2008, 19:2407-2413.
34. Pazar B., Ea H.K., Narayan S., Kolly L., Bagnoud N., Chobaz V., Roger T., Liote F., So A., Busso N. Basic calcium phosphate crystals induce monocyte/macrophage IL-1beta secretion through the NLRP3 inflammasome in vitro. J. Immunol. 2011, 186:2495-2502.
35. Qing Y.F., Zhang Q.B., Zhou J.G. Innate immunity functional gene polymorphisms and gout susceptibility. Gene 2013, 524:412-414.
36. Rabadi M.M., Kuo M.C., Ghaly T., Rabadi S.M., Weber M., Goligorsky M.S., Ratliff B.B. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am. J. Physiol. Ren. Physiol. 2012, 302:F730-F741.
37. Ryu E.S., Kim M.J., Shin H.S., Jang Y.H., Choi H.S., Jo I., Johnson R.J., Kang D.H. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am. J. Physiol. Ren. Physiol. 2013, 304:F471-F480.
38. Sakai Y., Otsuka T., Ohno D., Murasawa T., Sato N., Tsuruoka S. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren. Fail. 2014, 36:225-231.
39. Sanchez-Lozada L.G., Tapia E., Soto V., Avila-Casado C., Franco M., Zhao L., Johnson R.J. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol. Dial. Transplant. 2008, 23:1179-1185.
40. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
41. Wang H., Wei Y., Kong X., Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J. Ren. Nutr. 2013, 23:389-396.
42. Xiao J., Leung J.C., Chan L.Y., Guo H., Lai K.N. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. Nephrol. Dial. Transplant. 2009, 24:2067-2077.
43. Yang Z., Xiaohua W., Lei J., Ruoyun T., Mingxia X., Weichun H., Li F., Ping W., Junwei Y. Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. Am. J. Physiol. Ren. Physiol. 2010, 299:F336-F346.
44. Zhou Y., Fang L., Jiang L., Wen P., Cao H., He W., Dai C., Yang J. Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS ONE 2012, 7:e39738.
45. Zhuang Y., Feng Q., Ding G., Zhao M., Che R., Bai M., Bao H., Zhang A., Huang S. Activation of ERK1/2 by NADPH oxidase-originated reactive oxygen species mediates uric acid-induced mesangial cell proliferation. Am. J. Physiol. Ren. Physiol. 2014, 307:F396-F406.